COVID-19- Competitive Landscape, 2023

COVID-19- Competitive Landscape, 2023

DelveInsight’s, “COVID-19 - Competitive landscape, 2023,” report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

COVID-19: Understanding

COVID-19: Overview

Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans there are several known coronaviruses that cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

There are three main ways that COVID-19 can spread:

By breathing in air carrying droplets or aerosol particles that contain the SARS-CoV-2 virus when close to an infected person or in poorly ventilated spaces with infected persons

By having droplets and particles that contain the SARS-CoV-2 virus land on the eyes, nose, or mouth – especially through splashes and sprays like a cough or sneeze

By touching the eyes, nose, or mouth with hands that have the SARS-CoV-2 virus particles on them

Symptoms

A wide range of symptoms for COVID-19 have been reported. These symptoms include:

Fever or chills

Cough

Muscle or body aches

Anorexia

Sore throat

Nasal congestion or runny nose

Headache

Diarrhea

Nausea

Shortness of breath or difficulty breathing

Loss of smell or taste

COVID-19 Preventative Actions

COVID-19 can be prevented through pharmaceutical (i.e., vaccination) and non-pharmaceutical interventions (e.g., masking, physical distancing, hand hygiene). All of these preventative measures are important to protect individuals from acquiring and transmitting the SARS-CoV-2 virus and should be done in conjunction with one another.

Vaccination- Getting vaccinated is a preventative measure that people can take to avoid getting sick with COVID-19 and to avoid infecting others. While safe and effective vaccines are a great tool for prevention, it is important to continue other preventative actions such as wearing masks, performing hand hygiene, physically distancing from others, and avoiding crowded spaces and spaces with poor ventilation.

Masks- Wearing masks is another important preventative action for COVID-19 that should continue to be performed.

Other preventative actions- Even with the introduction of vaccinations as a tool for prevention against COVID-19 and the proper use of masks, CDC recommends the following key COVID-19 preventative activities: — avoiding crowded spaces or spaces that have poor ventilation or wear a mask in these spaces; performing proper hand hygiene; keeping high touch surfaces clean; monitoring symptoms; and getting tested if ill.

Report Highlights

In March 2023, Biophytis SA, a biotechnology company focused on the development of drugs to slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, signed a master service agreement with the pharmaceutical company Intsel Chimos, which will become its Pharmaceutical Operator/Exploitant in France for Sarconeos (BIO101) in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.

In March 2022, Akston Biosciences Corpand Biolexis, a division of Stelis Biopharma Ltd., entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452, a protein subunit COVID-19 vaccine. Biolexis gained the right to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa largely covering the low-and-middle-income countries (LMICs).

In February 2022, CEPI, the Coalition for Epidemic Preparedness Innovations, announced that it will expand its collaboration with Shanghai Zerun Biotechnology Co., Ltd. (Zerun Bio) and its parent company Walvax Biotechnology Co., Ltd. (Walvax), a public company listed on the Shenzhen Stock Exchange (300142.SZ) to advance the development of a COVID-19 variant vaccine. CEPI will invest up to an additional USD$8.15 million to support a Phase I/II clinical trial in Mali which will evaluate the safety and immunogenicity of Zerun Bio’s prototype and multi-variant vaccine candidates.

In June 2021, Siemens Healthineers announces its collaboration with Nanogen Pharmaceutical Biotechnology to utilize Siemens Healthineers SARS-CoV-2 IgG antibody test (sCOVG) in Nanogen’s Nanocovax vaccine clinical trials for COVID-19. This was a first-of-its-kind collaboration for Siemens Healthineers in Asia Pacific, which will facilitate the quantitative measurement of SARS-CoV-2 IgG antibodies in vaccinated subjects.

In 2021, Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19.

In April 2020, AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. Under the agreement, AstraZeneca would be responsible for development and worldwide manufacturing and distribution of the vaccine.

COVID-19: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd. is headquartered in Ahmedabad, India, Zydus Corporate Park. The group has manufacturing sites and research facilities spread across Gujarat, Maharashtra, Goa, and Himachal Pradesh, Sikkim in India, the USA, and Brazil. The Zydus Research Centre is the dedicated research arm of the Zydus Group. With its over 400 research professionals, ZRC spearheads the group's global quest to create healthier and happier communities. Vaccine Technology Centre of Zydus Cadila has a wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate, and other subunit vaccines for unmet needs.

Product Description: ZyCoV-D

ZyCoV-D is India's first indigenously developed plasma DNA vaccine targeted against COVID-19. In addition, ZyCoV-D is the world's first Plasmid DNA Vaccine authorized for COVID-19 prevention. Zydus Cadila announced it had applied for Emergency Use Authorization (EUA) to the office of the DCGI for ZyCoV-D on July 1, 2021.

The ZyCoV-D vaccine was developed by Zydus Cadila using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene and approved by the Drugs Controller General of India (DCGI) to conduct late-stage clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet® needle-free system, Tropis®, which can significantly reduce any side effects. Also, being a plasmid DNA vaccine, ZyCoV-D doesn't display vector-based immunity concerns, says the Company. A painless, needle-free injector delivers the immunization in a narrow fluid stream into the skin.

2. Company Overview: AstraZeneca

AstraZeneca, is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Product Description: AZD1222

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

In May 2020, AstraZeneca received support of more than $1bn from BARDA for the development, production and delivery of the vaccine under an agreement with the US Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. The vaccine has been granted a conditional marketing authorization or emergency use in more than 70 countries across six continents, and with the Emergency Use Listing granted by the World Health Organization this accelerates the pathway to access in up to 142 countries through the COVAX Facility.

3. Company Overview: BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Product Description: BNT162b2

BNT162b2, is comprised of a nucleoside modified messenger RNA (modRNA) encoding an optimized viral full-length spike (S) glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The S glycoprotein is the target of virus neutralizing antibodies. On August 23, 2021, FDA announced the first approval of a COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and the approved vaccine is marketed as Comirnaty, for the prevention of COVID-19 in individuals 12 years of age and older.

Comirnaty is a monovalent COVID-19 vaccine that is approved for use as a two-dose primary series for the prevention of COVID-19 in individuals 12 years of age and older. It is also authorized for emergency use to provide a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.

COVID-19: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Nobelpharma

Nobelpharma committed to development of critical but neglected drugs in order to fulfill social mandate. Nobelpharma have constantly been aspiring to conduct research and development of drugs that are not the prime targets for many pharmaceutical companies due to questionable economic viability with a small number of patients. Company development pipeline mainly includes the drugs such as orphan drugs that have been strongly requested by patients, academic societies, or the government, as well as off-label drugs and pediatric medicines.

Product Description: Sargramostim

Sargramostim is a man-made version of a particular natural substance made in the body. It is used to increase the production of white blood cells in the body. Sargramostim is given to people who have reduced abilities for producing white blood cells. It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). It is a supportive medication but does not help in the treatment of cancer. Currently the product is in Phase II/III stage of development for the treatment of COVID-19.

2. Company Overview: Staidson (Beijing) Biopharmaceuticals Co., Ltd

Staidson is a publicly-traded pharmaceutical company headquartered in Beijing, China, focusing on drug research and development (R&D), manufacturing and sales of innovative medicines with independent intellectual property rights. The company covers early stage exploratory research, drug discovery, process development and pilot scale-up, preclinical biological evaluation, clinical development to drug production and commercialization. Staidson is an innovative biopharmaceutical enterprise with a complete biopharma industrial chain, R&D facilities, and production and marketing systems. Staidson is a listed company on the Shenzhen Stock Exchange, China and a national high-tech enterprise.

Product Description: BDB-001

BDB-001, a monoclonal anti-C5a antibody is being developed by Staidson Beijing BioPharmaceuticals in collaboration with Beijing Defengrui Biotechnology Co. Ltd.

The drug is currently in Phase II/III stage of clinical trial evaluation to treat COVID-19 Pneumonia. It is being administered as intravenous infusion. BDB-001 specifically binds to C5a, so that C5a loses its ability to bind to its receptors, thereby blocking its biological functions, such as neutrophil chemotaxis, intracellular lysozyme release, increased levels of inflammatory factors and oxygen Respiratory bursts, while not affecting C5 cleavage and MAC formation.

3. Company Overview: NeuroActiva Inc.

NeuroActiva Inc. is a clinical stage bio-pharmaceutical company committed to the discovery and development of new drugs to prevent and treat Alzheimer's disease and Covid-19. NeuroActiva have developed patented neuroprotection and neurogenesis methods that can prevent and treat Alzheimer's disease, as well as combination therapy with anti-viral drugs to treat Covid-19.

Product Description: NA-831

The drug NA-831 is a small molecule drug that can be administered orally. The drug is an endogenous compound i.e. it already exists in the human brain. Basically, the drug is very safe and has no toxicity, suitable for long term treatment and prevention purpose. In November 2020, NeuroActiva initiated a Phase III randomized, double-blind, placebo-controlled, in order to evaluate the efficacy and safety of oral polio vaccine and NA-831 for prophylaxis and treatment of early onset of Covid-19. With the enrollment of 3600 participants the trial is in enrolling by invitation stage and expected to be completed by November 2022.

4. Company Overview: Nanogen Pharmaceutical Biotechnology

Established in 1997 and headquartered in Ho chi Minh City, Vietnam, Nanogen Pharmaceutical Biotechnology is a leading company that develops, manufactures and markets novel active Biopharmaceutical ingredients (APIs) based on advances in recombinant DNA and protein technologies. Nanogen offers a variety of gene-to-therapy biopharmaceuticals for the treatment of hepatitis B, hepatitis C, anemia due to chronic renal failure, oncology, etc. Its therapeutic injection products are developed, manufactured and marketed under strict compliance with current GMP and tight QC/QA procedures, and are sold in various countries in Asia, Europe, Africa and America.

Product Description: Nanocovax

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine (SARS‑CoV‑2 recombinant spike protein with aluminum adjuvant). Currently the product is in Phase III stage of development for Covid-19. Nanocovax completed 120 injections of Phase I clinical trials in 60 volunteers. The research team's representative presented the results that: all 3 injection doses of 25mcg, 50mcg and 75mcg have 100% safety, 90% protection against SARS-CoV-2 virus infection and all have good immunity. Currently the product is in Phase III stage of development for the prevention of Covid-19.

Further product details are provided in the report……..

COVID-19 Analytical Perspective by DelveInsight

In-depth Commercial Assessment: COVID-19 Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

COVID-19 Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

COVID-19 Report Assessment

Company Analysis

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing COVID-19 drugs?

How many COVID-19 drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for COVID-19 and their status?

What are the key designations that have been granted to the emerging and approved drugs?

Key Players

SARS-CoV-2 mRNA vaccine

Recombinant COVID-19 vaccine (Sf9 cells)

Tempol

AD17002

AKS-452

AG0302

rNAPc2

RUTI vaccine

MultiStem

Zavegepant

BIO101

Metenkefalin + Tridecactide

SCB-2019

TXA127

EB05

Sodium pyruvate

FB2001

GNR-099

GX 19N

TJ003234

IMU-838

Nangibotide

INO-4800

Adintrevimab

Meplazumab

SSD8432

ADM03820

ANA001

EDP 235

EOM613

EgyVax vaccine

EG-009

Covax-19

GS-5245

ChAdV68-S

Enuzovimab

Emricasan

IN B009

HH-120

BM-Allo.MSC

IMM-BCP-01

Key Products

Walvax Biotechnology

Westvac Biopharma

Adamis Pharmaceuticals

Advagene Biopharma

Akston Biosciences

AnGes Inc.

ARCA Biopharma, Inc.

Archivel Farma

Athersys

Biohaven Pharmaceuticals

Biophytis

Bosnalijek

Clover Biopharmaceuticals AUS Pty Ltd

Constant Therapeutics

Edesa Biotech

EmphyCorp

Frontier Biotechnologies Inc.

Generium

Genexine

I-MAB Biopharma

Immunic

Inotrem

Inovio Pharmaceuticals

Invivyd

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Jiangsu Simcere Pharmaceutical Co., Ltd.

National Resilience, Inc. (Ology Bioservices)

NeuroBo Pharmaceuticals Inc.

Enanta Pharmaceuticals

EOM PHARMACEUTICALS, INC.

Eva Pharma

Evergreen Therpeutics

GeneCure Biotechnologies

Gilead Sciences

Gritstone Oncology, Inc.

HiFiBiO Therapeutics

Histogen

HK inno.N

Huahui Health

ImmunityBio, Inc.

Immunome


Please Note: It will take 3-5 business days to complete the report upon order confirmation.